SubHero Banner

Daurismo (glasdegib)  – New drug approval

November 21, 2018 - The FDA announced the approval of Pfizer’s Daurismo (glasdegib), to be used in combination with low-dose cytarabine (LDAC), for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are ≥ 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.

Download PDF